Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 7/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 7/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998437 | 0.99 | THRB (0.44) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9998230 | 0.99 | THRB (0.44) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9997794 | 0.99 | THRB (0.44) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9998279 | 0.99 | THRB (0.44) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9997494 | 0.99 | THRB (0.44) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9997809 | 0.96 | ALDH1A1 (0.42) | THRBALDH1A1THRARARB | |
| SCHEMBL9998162 | 0.91 | THRB (0.40) | THRBALDH1A1KMT2A | |
| SCHEMBL9997739 | 0.85 | THRB (0.47) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9997736 | 0.85 | THRB (0.47) | THRBALDH1A1THRAMEN1KMT2A | |
| SCHEMBL9997488 | 0.85 | AKR1C3 (0.41) | ALDH1A1MEN1KMT2ACYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | THRB 926/4885ALDH1A1 160/4885THRA 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.